Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00128206 · ClinicalTrials.gov registry record · Phase 3
Treatment of Latent TB Infection for Jailed Persons
A Phase 3 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 3
- Development phase
- 364
- Enrollment target
NCT00128206 is a Phase 3 study that has completed, run by University of California, San Francisco. The registered enrollment target is 364 participants.
The verdict
NCT00128206, a Phase 3 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 364 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether an alternative drug, (rifampin) given daily, is better at treating tuberculosis (TB) and more tolerable than the usual drug treatment, isoniazid (INH). Study participants will include 972, TB infected, San Francisco Jail inmates, aged 18 or older. One group of volunteers will take INH two times a week for 9 months, and the other group will take rifampin daily for 4 months. Medication will be administered in jail and at the San Francisco TB Clinic if the volunteer is released from jail prior to completing the study. Participants will be seen daily for 4 months (rifampin group), and 2 times a week for 9 months (INH group) for directly observed therapy. Study procedures will include 5 symptom review visits and blood samples for lab testing. Follow-up will continue for each subject for five years after enrollment into the study.
Interventions
- DRUG Rifampin
- DRUG Isoniazid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 364 participants |
| Start Date | 2004-11 |
| Est. Completion | 2009-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00128206
The ClinicalTrials.gov registry entry for NCT00128206 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 364 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rifampin is the first listed.
NCT00128206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00128206 about?
NCT00128206 is a clinical study titled "Treatment of Latent TB Infection for Jailed Persons". The purpose of this study is to determine whether an alternative drug, (rifampin) given daily, is better at treating tuberculosis (TB) and more tolerable than the usual drug treatment, isoniazid (INH). Study participants will include 972, TB infected, San Francisco Jail inmates, aged 18 or older. On...
What is the current status of trial NCT00128206?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 364 participants. The study started on 2004-11. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00128206?
The interventions under investigation include: Rifampin (DRUG), Isoniazid (DRUG).
Who is sponsoring clinical trial NCT00128206?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.